{
  "docId": "019de071-f648-72d0-9c84-3373768bf908",
  "docSlug": "15eb2f0f83943ed61260bacd75adb779",
  "documentTitle": "ATAI | Investor Day Presentation Deck | 42 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 42,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The table maps study types (HV PK, Scopolamine, Peripheral Diabetic Neuropathy) against Phase 1/2 status and key clinical endpoints (Safety/PK, Target Engaged, Biphasic).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f648-72d0-9c84-3373768bf908/28",
  "deckHref": "/decks/019de071-f648-72d0-9c84-3373768bf908",
  "deckJsonHref": "/decks/019de071-f648-72d0-9c84-3373768bf908.json",
  "deckAnchorHref": "/decks/019de071-f648-72d0-9c84-3373768bf908#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.65,
        "x": 0.09,
        "y": 0.48
      },
      "kind": "list",
      "text": "Excellent PK and CSF exposure; >500 subjects exposed (9 prior Phase 1 and 2 studies); Safety to 6 month (300 mg TID); Multiple independent cognitive signals (30-80 mg dose range)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f31c0358-189f-406c-b4e0-1df6b359f566",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.82,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "table",
      "text": "Study, Phase 1, Phase 2, Safety/PK, Target Engaged, Biphasic",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02eb374b-7ef0-43ec-b4fb-e1d7da47ea09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.78
      },
      "kind": "title",
      "text": "Cognitive improvements seen at the lowest doses in prior studies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cc851ee-3120-4232-9e83-19544aca38d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "RL – 007 development: excellent PK, well tolerated with replicated cognitive signals",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c86fdd5-9047-4ca2-a55c-3e804d749fb7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 21,
      "beatId": "7effda0b-3140-4201-ba8c-40b7efb15914",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 21-28 present RL-007 as a potential solution, highlighting its de-risked profile, positive pre-clinical results, and promising phase 2a data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}